Somewhere between the headlines and the clinic sits a population of people the health system barely sees. They train hard, they read forum threads that most GPs have never opened, and they use performance-enhancing compounds without the biomarkers, supervision, or honest conversation that would make that use safer. The scale of this gap is the reason SafePulse exists.
Recent surveys put the UK population who have used anabolic steroids at somewhere between half a million and a million people — a figure that has grown most sharply among users chasing an aesthetic outcome rather than competing in a sport. Peptides, SARMs and other compounds sit alongside that, often layered in ways the original research never modelled. The evidence base for safe use is thin. The community conversations that fill the vacuum are mixed at best.
The existing system responds to this largely with silence. GPs rarely receive formal training on performance-enhancing drugs beyond the category label on their prescribing software. The NHS has no recognised pathway for harm-reduction bloods or dose review. Abstinence is the default message, and for users who have already decided to continue, an abstinence-only conversation ends the consultation rather than starting it.
Harm reduction is a different posture. It says: you are going to do this — let us make sure you do it with the right monitoring, the right information, and a clinician who will not judge you for walking in the door. For performance enhancement specifically, that looks like a short list of concrete interventions: a baseline lipid and hormone panel, a follow-up panel mid-cycle, education on the compounds being taken, an honest read on risk, and a human being to speak to when something feels wrong.
SafePulse is the UK Community Interest Company being built around those interventions. Our clinical work runs with Chelsea Medical Practice. Our lab partner is Eurofins. Our research collaborators include clinicians and academics who have chosen to put their names to an evidence-led, non-judgemental approach because the alternative — continued silence — has produced a generation of users who trust forums more than they trust doctors.
The work is not quick. The evidence we want will take years to assemble. The clinical capacity we want to see in practices across the UK has to be built, one trained clinician at a time. And public perception of this population will have to shift before policy catches up. But the gap is real, it is widening, and the choice is either to close it with evidence or let it be filled by the next low-quality source to go viral. We have chosen the first.